Federal grants to Starlight Cardiovascular, Inc.
Starlight Cardiovascular, Inc. in San Diego, California received $6.7 million in federal grants from fiscal 2021 to 2025, across 5 awards. Its largest program was Cardiovascular Diseases Research, with $6.7 million. In fiscal 2025 it was awarded $2.0 million.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$6.7 million
- Awards5
- Awarded in FY 2025$2.0 million
- Largest award$3.2 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 1 | $492,571 |
| FY 2022 | 2 | $1.7 million |
| FY 2023 | 1 | $901,548 |
| FY 2024 | 2 | $1.6 million |
| FY 2025 | 2 | $2.0 million |
Programs that fund Starlight Cardiovascular, Inc.
| Program | Awards | Amount |
|---|---|---|
| Cardiovascular Diseases Research | 5 | $6.7 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 5 | $6.7 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Ductus arteriosus stent to improve congenital heart defect mortality - abstract the technical challenges faced by pediatric cardiovascular physicians (surgeons and interventionalists alike) have long been ignored, forcing them to use devices designed for adults and different conditions to treat aili | Cardiovascular Diseases Research | September 19, 2022 | $3.2 million |
| Development of a pulmonary flow restrictor for hypoplastic left heart syndrome - abstract starlight cardiovascular is developing what will be the first fda approved percutaneous flow restrictor to replace surgical banding in congenital heart disease (CHD). Many babies with chds such as hypoplastic l | Cardiovascular Diseases Research | March 20, 2024 | $2.1 million |
| Commercialization readiness for ductus arteriosus stent to improve congenital heart defect mortality - abstract the technical challenges faced by pediatric cardiovascular physicians (surgeons and interventionalists alike) have long been ignored, forcing them to use devices designed for adults and di | Cardiovascular Diseases Research | September 15, 2024 | $500,000 |
| Ductus arteriosus stent to improve congenital heart defect mortality - abstract the technical challenges faced by pediatric cardiovascular physicians (surgeons and interventionalists alike) have long been ignored, forcing them to use devices designed for adults and different conditions to treat aili | Cardiovascular Diseases Research | August 6, 2021 | $492,571 |
| Development of a pulmonary flow restrictor for hypoplastic left heart syndrome - abstract starlight cardiovascular is developing what will be the first fda approved percutaneous flow restrictor to replace surgical banding in congenital heart defects (CHD), including hypoplastic left heart syndrome ( | Cardiovascular Diseases Research | February 15, 2022 | $448,000 |
Questions people ask
How much federal grant money does Starlight Cardiovascular, Inc. get?
$6.7 million in 5 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Starlight Cardiovascular, Inc. the most?
The Department of Health and Human Services, with $6.7 million in 5 awards.
What is Starlight Cardiovascular, Inc.'s largest federal grant?
$3.2 million under Cardiovascular Diseases Research, with its first action in the period on September 19, 2022. That counts only the money obligated in fiscal 2021 to 2025.
Other grant recipients in San Diego
- San Diego Association of Governments
- Metropolitan Transit System
- General Atomics
- Neighborhood House Association
- San Diego County Regional Airport Authority
- San Diego State University Foundation
- San Diego Unified School District
- Family Health Centers of San Diego Inc
Largest federal grant recipients in California · Federal grants in California